[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"squamous-cell-carcinoma-of-oropharynx\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:squamous-cell-carcinoma-of-oropharynx":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,65],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100579203","patients-with-human-papillomavirus-associated-head-and-neck-cancer-for-the-discovery-of-predictive-biomarkers-to-guide-clinical-intervention-100579203",false,"NCT06821243","Patients With Human Papillomavirus-associated Head and Neck Cancer for the Discovery of Predictive Biomarkers to Guide Clinical Intervention","Multidimensional Assessment of Virus-associated Head and Neck Cancer Patients for the Discovery of Predictive Biomarkers to Guide Clinical Intervention","Inclusion Criteria:\n\n* Squamous cell carcinomas of the oropharynx (OPSCC) candidates for surgical\n* Age \\> 18 years\n* ECOG performance status \\\u003C\\_ 2\n* Signature of informed consent (to participate in the study and data processing)\n\nExclusion Criteria:\n\n* Presence of distant metastases at the time of diagnosis\n* Previous head and neck cancer","ALL","18 Years",{"count":19,"type":20},40,"ESTIMATED","OBSERVATIONAL","Prospective pilot study, non-interventional, of a biological\u002Fradiological nature, which involves the collection of tissue samples, and blood from patients suffering from squamous cell carcinoma of the oropharynx OPSCC for detection of HPV-DNA\u002FRNA and immuno-phenotypic analysis of T cells, study of extracellular vesicles, and dosages of cytokines and chemokines involved in the immune response",[24],"Squamous Cell Carcinoma of Oropharynx",[26,27,28],"carcinoma of the oropharynx","squamous cell carcinoma of the oropharynx","head and neck","RECRUITING","2026-06-04",{"date":32,"type":33},"2026-06-05","ACTUAL",{"date":35,"type":33},"2024-07-24",{"date":37,"type":20},"2026-07-24",{"name":39,"class":40},"Regina Elena Cancer Institute","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":41},"100588919","immune-biomarker-study-for-cisplatin-ineligible-patients-receiving-chemoradiotherapy-with-docetaxel-100588919","NCT06947668","Immune Biomarker Study for Cisplatin-ineligible Patients Receiving Chemoradiotherapy With Docetaxel","DoIT_Neck","Inclusion Criteria:\n\n* Patients with squamous cell carcinomas of the oropharynx, larynx and oral cavity for whom definitive or postoperative chemoradiation is indicated\n* Patients who are cisplatin-unfit for chemotherapy, defined as:\n\n  * ECOG 2\n  * Organ dysfunction ≥ 2 according to National Cancer Institute Common Toxicity Criteria (NCI CTC) Version 4.0, such as hearing loss or tinnitus or neurological diseases\n  * Calculated creatinine clearance of ≤50ml\u002Fmin\n  * Impaired organ function or comorbidities that preclude the use of cisplatin, e.g.: left ventricular ejection fraction \\\u003C 50%, uncorrectable renal insufficiency with elevated creatinine despite creatinine clearance of 50ml\u002Fmin due to increased body weight, uncontrolled hypertension\n  * Poor nutritional status BMI \\\u003C 16kg\u002Fm²\n  * Concomitant use of nephrotoxic drugs that cannot be discontinued or converted due to other illnesses.\n  * Willingness of patients to provide blood, saliva and stool samples and consent to the preservation of all samples for study purposes\n  * Age ≥ 18 years\n  * Sufficient cognitive abilities of the patients to understand the purpose of the study and to consent to it\n\nExclusion Criteria:\n\n* Distant metastases at the time of diagnosis and simultaneous second cancers, i.e. at the time of study inclusion\n* Malignancies in the last 5 years regardless of location (except basal cell carcinoma or cervical uteri)\n* Carcinomas in which no sample collection is possible or likely without compromising the pathological assessment\n* Persistent drug or medication abuse\n* Patients who are unwilling or unable to comply with the protocol and receive treatment\n* Patients who are unsuitable for participation in the study due to a language barrier",{"count":50,"type":20},250,"Analysis of tumor tissue (which is already available in pathology) and collection of saliva\u002Fstool and blood samples, which are obtained as part of a routine collection. These will be evaluated together with the patients' clinical data to identify possible predictors for treatment feasibility, survival, tumor control and potentially increased tumor immunogenicity by docetaxel.",[24,53,54,55],"Squamous Cell Carcinoma of the Hypopharynx","Larynx Squamous Cell Carcinoma","Oral Cavity Squamous Cell Carcinoma","2026-03-11",{"date":58,"type":33},"2026-03-12",{"date":60,"type":33},"2025-05-01",{"date":62,"type":20},"2030-12-31",{"name":64,"class":40},"University of Erlangen-Nürnberg Medical School",{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":82,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":96},"100586412","cthpvdna-in-hpv-positive-squamous-cell-carcinoma-of-the-oropharynx-100586412","NCT06915038","ctHPVDNA in HPV Positive Squamous Cell Carcinoma of the Oropharynx","Circulating Tumor HPV DNA Driven Adjuvant Treatment Deintensification After Transoral Surgery for HPV-Positive Squamous Cell Carcinoma of the Oropharynx","Inclusion Criteria:\n\nPre-Surgery\n\n* Subjects ≥ 18 years old at the time of informed consent.\n* Ability to provide written informed consent and HIPAA authorization.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n* Primary tumor of the oropharynx (palatine tonsil, tongue base, soft palate, lateral or posterior walls of oropharynx).\n* Histopathologically confirmed squamous cell carcinoma.\n* Detectable ctHPVDNA from blood samples collected prior to treatment.\n* Resectable and accessible tumor with high probability of achieving negative margins.\n* Smokers and non-smokers included.\n* Tumor stage (AJCC 8th edition): T1 or T2, and select T3 tumors that are mobile and do not invade the larynx.\n* Nodal stage (AJCC 8th edition): N0, N1 or N2.\n* Mobile neck nodes on physical exam if N positive.\n* HPV+ tumor, as determined by p16, in-situ hybridization, real-time polymerase chain reaction, or ctHPVDNA.\n\nPost-Surgery\n\n• Subjects with unknown primaries included if primary is definitively identified and resectable with negative margins or if the palatine and lingual tonsils are thoroughly resected and pathologically proven to be negative for a primary.\n\nExclusion Criteria:\n\n* Serious medical condition preventing general anesthesia for surgery.\n* History of previous head and neck radiation or previous head and neck cancer within 3 years.\n* Distant metastatic disease present.\n* Subjects with synchronous HPV+ oropharynx primaries\n* Prior invasive malignant disease within 3 years, with the exception of non-melanoma skin cancer and thyroid cancer, unless patient is deemed cured or disease free, in which case patient may be included in the study.\n* Lactating or pregnant women. Women of childbearing potential must have a negative pregnancy test on the day of surgery. Women are considered to have childbearing potential (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) unless they meet one of the following criteria:\n\n  1. Has undergone a hysterectomy or bilateral oophorectomy; or\n  2. Has been naturally amenorrheic for at least 12 consecutive months.",{"count":73,"type":20},120,"INTERVENTIONAL",[76],"NA","This study is a prospective phase II trial, designed to assess the efficacy and feasibility of adjuvant treatment deintensification guided by ctHPVDNA levels for patients with HPV+OPSCC who undergo transoral surgery and neck dissection.",[24,79,80,81],"HPV Positive Cancer","Throat Cancer","Tonsil Cancer",[83,84,85,86],"NavDX","HPVctDNA","HPV","transoral surgery","2025-07-28",{"date":89,"type":33},"2025-07-31",{"date":91,"type":33},"2025-06-11",{"date":93,"type":20},"2028-12",{"name":95,"class":40},"Indiana University",2]